Results from BILCAP, comparing adjuvant capecitabine to observation following resection of biliary tract cancers, showed a trend for improved median OS (51.1 months vs. 36.4 months) as well as RFS (24.4 months vs. 17.5 months) with the addition of post-operative capecitabine.
← all excerpts
The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma.
1
—
—